Condition

Sjogren Syndrome

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 31 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials31

Recruiting9

Common interventions25

Lead sponsors shown15

Clinical trials

31 shown

Fatigue in Sjögren's Syndrome: 3 Therapeutic StrategiesNCT06875102 · 2026-03-24

TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENENCT07153276 · 2026-02-27

Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune DiseasesNCT07301164 · 2025-12-11

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114 · 2025-07-09

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune DiseasesNCT06828042 · 2025-07-01

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesNCT06794008 · 2024-12-26

Rare AutoImmune SElf-management Programme DevelopmentNCT06642870 · 2024-10-01

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease PatientsNCT07249060 · 2024-01-08

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVONCT03816345 · 2019-07-16

Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren SyndromeNCT07838454 · 2026-12-01

NOT_YET_RECRUITING

Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye DiseaseNCT07671222 · 2026-12-01

NOT_YET_RECRUITING

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune DiseasesNCT06821659 · 2026-11-01

NOT_YET_RECRUITING

Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's SyndromeNCT06877546 · 2025-05-24

ACTIVE_NOT_RECRUITING

Temporomandibular Joint Dysfunction in Sjögren's SyndromeNCT07248306 · 2025-05-15

"Validity and Reliability of Pelvic Floor Distress Inventory-20 in Primary Sjögren's Syndrome"NCT07248436 · 2025-03-28

"Core Stabilization Strenght and Pelvic Floor Functions in Primary Sjogren's"NCT06879444 · 2025-02-05

ENROLLING_BY_INVITATION

Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR)NCT06680310 · 2024-12-01

NOT_YET_RECRUITING

Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Treatment Method for Sjogren's Syndrome (SS)NCT06626477 · 2024-11-05

Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye.NCT06931041 · 2024-02-01

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeNCT05349214 · 2022-08-04

ACTIVE_NOT_RECRUITING

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's SyndromeNCT05350072 · 2022-07-28

Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.NCT05124925 · 2022-07-27

A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)NCT04988087 · 2021-11-30

The Feasibility of Multispectral Optoacoustic Tomography in Different DiseasesNCT06740175 · 2020-04-07

Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren SyndromeNCT03865888 · 2018-10-30

Minor Salivary Gland Transplantation for Cicatrizing ConjunctivitisNCT03839069 · 2016-09-01

Pregnancy and Medically Assisted Conception in Rare DiseasesNCT02450396 · 2015-06-01

Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry EyeNCT02257957 · 2014-11-30

Green Tea Lozenges for the Management of Dry MouthNCT01647737 · 2011-03-01

Treatment of Dry Eye Using 0.03% Tacrolimus Eye DropsNCT01850979 · 2010-02-01

Cross-sectional Study of Use of Speckle Method in Early Diagnosis of Cardiovascular DysfunctionNCT02132585 · 2010-01-01

Common interventions

Leading sponsors

Novartis Pharmaceuticals 4 Pamukkale University 3 Peking University Third Hospital 3 Instituto de Oftalmología Fundación Conde de Valenciana 2 University of Sao Paulo General Hospital 2 Abilion Medical Systems AB 1 Artiva Biotherapeutics, Inc. 1 Assistance Publique - Hôpitaux de Paris 1 Augusta University 1 Banu Erkal 1 Centre Hospitalier Universitaire de Saint Etienne 1 Hospital Universitario Araba 1 Koite Health Oy 1 National Cancer Institute (NCI) 1 National Taiwan University Hospital 1

Trial status mix

COMPLETED11

RECRUITING9

NOT_YET_RECRUITING4

ACTIVE_NOT_RECRUITING2

UNKNOWN2

ENROLLING_BY_INVITATION1

TERMINATED1

WITHDRAWN1

Phase mix

PHASE29

NA5

PHASE35

PHASE14

PHASE42

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.